SCM
KERX

Stevens Capital Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Stevens Capital Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-25,699
Closed -$364K – 1355
2014
Q4 		$364K Buy
+25,699
New +$398K 0.01% 660
2013
Q3 		– Sell
-17,461
Closed -$130K – 1287
2013
Q2 		$130K Buy
+17,461
New +$136K ﹤0.01% 847

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Stevens Capital Management's KERX Position: Q1 2015 in Review

Stevens Capital Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2015, closing a stake of 25,699 shares — an estimated $364K sold.

Stevens Capital Management first reported a position in KERX in Q2 2013 and held it in 2 quarters. The position peaked at $364K in Q4 2014. 157 funds tracked by Wall St. Rank hold KERX as of Q1 2015.

  • Stevens Capital Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2015 after selling out during the quarter.
  • Stevens Capital Management sold 25,699 Keryx Biopharmaceuticals Inc shares in Q1 2015, an estimated $364K.
  • Stevens Capital Management first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 2 quarters.
  • Stevens Capital Management's Keryx Biopharmaceuticals Inc position peaked at $364K in Q4 2014.
  • 157 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2015.

Based on Stevens Capital Management's 13F filing for Q1 2015, filed 7 May 2015.